Antibodies News and Research

RSS

Multi-center Phase I study of anti-VISTA opens for patient enrollment

Dartmouth and Dartmouth-Hitchcock Norris Cotton Cancer Center will serve as one of the lead institutions for a new multi-center clinical trial of anti-VISTA, now open and recruiting for patient enrollment.

7 Oct 2020

Case report of arthritis in a COVID-19 patient

The current paper published in the The Lancet Rheumatology discusses arthritis in a 58-year-old white woman with COVID-19 of less than severe intensity.

7 Oct 2020

Study shows how CD4+ T cells respond to SARS-CoV-2 virus

As scientists around the world develop life-saving COVID-19 vaccines and therapies, many are still wondering exactly why the disease proves deadly in some people and mild in others.

7 Oct 2020

Dried blood spot samples accurately detect anti-SARS-CoV-2 S glycoprotein antibodies

Using dried blood spot samples (DBS) is an accurate alternative to venous blood in detecting SARS-CoV-2 antibody tests, a new study by immunology experts at the University of Birmingham has found.

6 Oct 2020

Thiopurines could help stop viral replication in human coronaviruses

Researchers from the Department of Microbiology & Immunology, Dalhousie University, University of Calgary, and Department of Biochemistry and Molecular Biology, University of British Columbia, Canada, worked with human coronaviruses in cell cultures to look for drugs that might prevent accumulation and replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

6 Oct 2020

Cats and dogs are low risk for SARS-CoV-2 transmission to humans

Researchers from the College of Veterinary Medicine and Biomedical Sciences, Colorado State University studied the possible transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among domestic cats and dogs.

5 Oct 2020

Production of six monoclonal antibodies against SARS-CoV-2 spike protein

Youjia Guo et al. in a recent bioRxiv preprint paper demonstrate the robust performance of mouse anti-SARS-CoV-2 spike monoclonal antibodies in immunoassays, including western blotting, ELISA, immunofluorescence, and immunoprecipitation and also neutralizing activity in vitro against SARS-CoV-2 infection.

5 Oct 2020

Eli Lilly's LY-CoV555 antibody shows potential as COVID-19 treatment

Researchers in the United States and Canada have discovered a monoclonal antibody that potently neutralizes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent responsible for the current coronavirus disease 2019 (COVID-19) pandemic.

5 Oct 2020

Less than 10% of US adults have SARS-CoV-2 antibodies

A new study by researchers at Stanford University and Ascend Clinical Laboratory and published in the journal The Lancet in September 2020 reports the prevalence of antibodies to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in a dialysis patient population in the US.

5 Oct 2020

Two phase II clinical trials suggest potential new treatment options for metastatic cervical cancer

Preliminary results from two independent, phase II clinical trials investigating a new PD-1 (programmed cell death protein 1)-based immune therapy for metastatic cervical cancer suggest potential new treatment options for a disease that currently has limited effective options and disproportionately impacts younger women.

5 Oct 2020

Advanced model reveals dynamic motions of SARS-COV-2 spike-shielding glycans

A recent paper published on the preprint server bioRxiv in September 2020 discusses the dynamic interactions of the spike protein glycan shield, which may be of great value in developing therapeutic compounds to fight severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

5 Oct 2020

Another study finds cross-reactivity T cell responses against SARS-CoV-2

Using ELISpot and proliferation assays, researchers show strong responses in SARS-CoV-2 infected patients, but not so much in negative samples. However, there may be cross-reactive T cell responses from other human coronaviruses.

5 Oct 2020

AbC-19 blood test detects COVID-19 antibodies 20 weeks after first symptoms/PCR positive result

Serological antibody immunoassays are one of the essential tools to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In a new study, Immunoglobulin G (IgG) antibodies are detected in a large cohort, lasting up to 140 days. The researchers propose an alternative to reverse transcription-polymerase chain reaction (RT-PCR) positive status as a standard for assessing SARS-CoV-2 antibody assays and show robust performance metrics for the AbC-19 rapid test.

5 Oct 2020

Investigation of SARS-CoV-2 antibody responses in patients with aggressive hematological malignancies

Patients with hematological malignancy (PHM), also infected with COVID-19, were investigated for SARS-CoV-2 antibody responses while undergoing systemic anti-cancer therapy. While no obvious correlation is found between the serological results and the hematological diagnosis and the treatment, the immune response is similar to the severity of COVID-19 infection observed in the general population.

4 Oct 2020

New multiplexed test with a low-cost sensor may enable at-home COVID diagnosis

One feature of the COVID-19 virus that makes it so difficult to contain is that it can be easily spread to others by a person who has yet to show any signs of infection.

1 Oct 2020

Researchers receive NCI grant to study role of collagens in breast cancer

An MUSC Hollings Cancer Center researcher received a $3 million grant from the National Cancer Institute to study how patterns of collagens can serve as biomarkers of breast cancer risk and potentially reveal clues to what might be driving health disparities.

1 Oct 2020

Investigational mRNA vaccine to prevent SARS-CoV-2 shows promise in older adults

A Phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection has shown that the vaccine is well-tolerated and generates a strong immune response in older adults.

30 Sep 2020

Researchers identify the target structures for T-cell response against SARS-CoV-2

Our immune system can efficiently fend off viral diseases. Two types of immune cells play an important role in this process: The T-cells, which firstly can directly destroy virus-infected cells and secondly enable the formation of efficient, virus-neutralizing antibodies by B-cells.

30 Sep 2020

SARS-CoV-2 D614G variant enhances infectivity, replication and transmission

Researchers in the United States and Japan have conducted a study showing a common mutation in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - the agent that causes coronavirus disease 2019 (COVD-19) - enhances the infectivity, replication, and early transmission of the virus.

30 Sep 2020

Newly developed fusion protein could improve COVID-19 research

Researchers at the Paul Scherrer Institute in Switzerland have developed a high-quality recombinant virus protein that could be applied in the development of vaccines against the 2019 novel coronavirus (2019-nCoV) and in the detection of novel viruses or antibodies.

30 Sep 2020